BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 524 filers reported holding BIO-TECHNE CORP in Q2 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $3,972,921 | +1.6% | 55,449 | -0.2% | 0.41% | +7.9% |
Q1 2024 | $3,909,039 | +9.5% | 55,534 | +20.1% | 0.38% | -2.6% |
Q4 2023 | $3,569,344 | +13.0% | 46,259 | -0.3% | 0.39% | +1.8% |
Q3 2023 | $3,159,741 | -30.4% | 46,419 | -16.5% | 0.38% | -27.0% |
Q2 2023 | $4,538,955 | +10.0% | 55,604 | 0.0% | 0.53% | +4.2% |
Q1 2023 | $4,125,261 | -10.9% | 55,604 | -0.5% | 0.50% | -4.7% |
Q4 2022 | $4,631,003 | +14.9% | 55,876 | +293.6% | 0.53% | -4.2% |
Q3 2022 | $4,032,000 | -18.2% | 14,196 | -0.1% | 0.55% | -12.6% |
Q2 2022 | $4,928,000 | -20.1% | 14,216 | -0.1% | 0.63% | -10.5% |
Q1 2022 | $6,165,000 | -16.9% | 14,236 | -0.7% | 0.71% | -14.8% |
Q4 2021 | $7,417,000 | +6.2% | 14,336 | -0.5% | 0.83% | -2.6% |
Q3 2021 | $6,985,000 | +6.6% | 14,414 | -1.0% | 0.85% | +10.5% |
Q2 2021 | $6,553,000 | +17.7% | 14,554 | -0.1% | 0.77% | +7.7% |
Q1 2021 | $5,566,000 | +20.0% | 14,574 | -0.2% | 0.72% | +13.3% |
Q4 2020 | $4,639,000 | +28.2% | 14,609 | 0.0% | 0.63% | +16.0% |
Q3 2020 | $3,619,000 | -6.2% | 14,609 | 0.0% | 0.54% | -11.4% |
Q2 2020 | $3,858,000 | +38.9% | 14,609 | -0.3% | 0.62% | +21.5% |
Q1 2020 | $2,778,000 | -13.6% | 14,649 | 0.0% | 0.51% | +7.7% |
Q4 2019 | $3,216,000 | +12.2% | 14,649 | 0.0% | 0.47% | +7.6% |
Q3 2019 | $2,866,000 | -11.9% | 14,649 | -6.1% | 0.44% | -13.5% |
Q2 2019 | $3,252,000 | +5.0% | 15,599 | 0.0% | 0.50% | +2.9% |
Q1 2019 | $3,097,000 | +42.5% | 15,599 | +3.8% | 0.49% | +53.9% |
Q4 2018 | $2,174,000 | -30.4% | 15,024 | -1.8% | 0.32% | -22.8% |
Q3 2018 | $3,123,000 | +31.3% | 15,299 | -4.8% | 0.41% | +20.1% |
Q2 2018 | $2,378,000 | -1.2% | 16,073 | +0.9% | 0.34% | -5.5% |
Q1 2018 | $2,407,000 | -99.9% | 15,933 | 0.0% | 0.36% | +11.3% |
Q4 2017 | $2,064,000,000 | – | 15,933 | – | 0.33% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |